Amneal Sets $200m Sales Ambition For Biosimilar Trio
Looking To Expand Portfolio With Licensing Deals For Early-Entry Opportunities
Amneal management has offered additional detail on the firm’s burgeoning biosimilars business, revealing a “peak” sales estimate of $200m for its current roster of three products as well as indicating plans to expand its pipeline both through licensing and internal development.
